Successful preventive treatment with cyclosporine in a patient with relapsed/refractory immune-mediated thrombotic thrombocytopenic purpura: a case report and review of the literature

[1]  M. Matsumoto,et al.  Rituximab prolongs the time to relapse in patients with immune thrombotic thrombocytopenic purpura: analysis of off-label use in Japan , 2020, International Journal of Hematology.

[2]  S. Vesely,et al.  ISTH guidelines for treatment of thrombotic thrombocytopenic purpura , 2020, Journal of thrombosis and haemostasis : JTH.

[3]  B. Lämmle,et al.  Open ADAMTS13, induced by antibodies, is a biomarker for subclinical immune-mediated thrombotic thrombocytopenic purpura. , 2020, Blood.

[4]  M. Murata,et al.  HLA loci predisposing to immune TTP in Japanese: potential role of the shared ADAMTS13 peptide bound to different HLA-DR. , 2020, Blood.

[5]  Shruti Chaturvedi,et al.  How targeted therapy disrupts the treatment paradigm for acquired TTP - the risks, benefits and unknowns. , 2019, Blood.

[6]  Flora Peyvandi,et al.  Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura , 2019, The New England journal of medicine.

[7]  B. Lämmle,et al.  Relapse Rate in Survivors of Acute Autoimmune Thrombotic Thrombocytopenic Purpura Treated with or without Rituximab , 2018, Thrombosis and Haemostasis.

[8]  J. George,et al.  Cyclosporine or steroids as an adjunct to plasma exchange in the treatment of immune-mediated thrombotic thrombocytopenic purpura. , 2017, Blood advances.

[9]  Y. Miyakawa,et al.  Diagnostic and treatment guidelines for thrombotic thrombocytopenic purpura (TTP) 2017 in Japan , 2017, International Journal of Hematology.

[10]  P. Coppo,et al.  Thrombotic thrombocytopenic purpura. , 2017, Blood.

[11]  Ang Li,et al.  Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study. , 2017, The Lancet. Haematology.

[12]  W. Clark,et al.  Treatment of severe, refractory and rapidly evolving thrombotic thrombocytopenic purpura , 2016, BMJ Case Reports.

[13]  Mitsuru Murata,et al.  Efficacy and safety of rituximab in Japanese patients with acquired thrombotic thrombocytopenic purpura refractory to conventional therapy , 2016, International Journal of Hematology.

[14]  A. ten Brinke,et al.  CD4+ T cells from patients with acquired thrombotic thrombocytopenic purpura recognize CUB2 domain-derived peptides. , 2016, Blood.

[15]  B. Chong,et al.  A novel triple therapy for ITP using high-dose dexamethasone, low-dose rituximab, and cyclosporine (TT4). , 2015, Blood.

[16]  M. Çetiner,et al.  Cyclosporin A therapy on idiopathic thrombotic thrombocytopenic purpura in the relapse setting: two case reports and a review of the literature , 2013, Transfusion.

[17]  A. ten Brinke,et al.  Preferential HLA-DRB1*11-dependent presentation of CUB2-derived peptides by ADAMTS13-pulsed dendritic cells. , 2012, Blood.

[18]  J. Voorberg,et al.  The macrophage mannose receptor promotes uptake of ADAMTS13 by dendritic cells. , 2012, Blood.

[19]  G. Choukroun,et al.  Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center , 2012, Critical care medicine.

[20]  Gerald McGwin,et al.  Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. , 2012, Arthritis and rheumatism.

[21]  J. Voorberg,et al.  Residues Arg568 and Phe592 contribute to an antigenic surface for anti-ADAMTS13 antibodies in the spacer domain , 2011, Haematologica.

[22]  F. Lansigan,et al.  Microangiopathic haemolytic anaemia resembling thrombotic thrombocytopenic purpura in systemic lupus erythematosus: the role of ADAMTS13. , 2011, Rheumatology.

[23]  S. Hidaka,et al.  Successful Treatment with Cyclosporine of Thrombotic Thrombocytopenic Purpura Refractory to Corticosteroids and Plasma Exchange , 2011, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[24]  D. Consonni,et al.  Different clinical severity of first episodes and recurrences of thrombotic thrombocytopenic purpura , 2010, British journal of haematology.

[25]  S. Ferrari,et al.  IgG subclass distribution of anti‐ADAMTS13 antibodies in patients with acquired thrombotic thrombocytopenic purpura , 2009, Journal of thrombosis and haemostasis : JTH.

[26]  K. Jhaveri,et al.  Treatment of refractory thrombotic thrombocytopenic purpura using multimodality therapy including splenectomy and cyclosporine. , 2009, Transfusion and Apheresis Science.

[27]  A. Nosari,et al.  Cyclosporine therapy in refractory/relapsed patients with thrombotic thrombocytopenic purpura , 2009, American journal of hematology.

[28]  J. George,et al.  Effect of prophylactic cyclosporine therapy on ADAMTS13 biomarkers in patients with idiopathic thrombotic thrombocytopenic purpura , 2008, American journal of hematology.

[29]  J. George,et al.  Ciclosporin and plasma exchange in thrombotic thrombocytopenic purpura: long‐term follow‐up with serial analysis of ADAMTS13 activity , 2007, British journal of haematology.

[30]  É. Oksenhendler,et al.  Prognostic value of anti-ADAMTS 13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS 13 activity. , 2007, Blood.

[31]  J. George,et al.  An evaluation of ciclosporin and corticosteroids individually as adjuncts to plasma exchange in the treatment of thrombotic thrombocytopenic purpura , 2007 .

[32]  J. George,et al.  An evaluation of cyclosporin and corticosteroids individually as adjuncts to plasma exchange in the treatment of thrombotic thrombocytopenic purpura. , 2007, British journal of haematology.

[33]  T. Matsuyama,et al.  Novel monoclonal antibody‐based enzyme immunoassay for determining plasma levels of ADAMTS13 activity , 2006, Transfusion.

[34]  J. George,et al.  An evaluation of cyclosporine alone for the treatment of early recurrences of thombotic thrombocytopenic purpura , 2006, Journal of thrombosis and haemostasis : JTH.

[35]  K. Remes,et al.  Excellent response of refractory life-threatening thrombotic thrombocytopenic purpura to cyclosporine treatment. , 2004, Clinical and laboratory haematology.

[36]  B. Borisch,et al.  Mechanism of action of rituximab , 2002, Anti-cancer drugs.

[37]  Yong,et al.  Successful use of cyclosporine A in the treatment of refractory thrombotic thrombocytopenic purpura , 1998, British journal of haematology.

[38]  J. Damoiseaux,et al.  Multiple effects of cyclosporin A on the thymus in relation to T-cell development and autoimmunity. , 1997, Clinical immunology and immunopathology.

[39]  J. Brennan,et al.  Refractory thrombotic thrombocytopenic purpura treated with cyclosporine , 1996, American journal of hematology.

[40]  N. Maurin,et al.  Cyclosporine for Thrombotic Thrombocytopenic Purpura , 1993, Annals of Internal Medicine.

[41]  H. Mcdevitt,et al.  Autoimmune diseases: the failure of self tolerance. , 1990, Science.